Mónica Rodríguez-Jiménez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mónica Rodríguez-Jiménez has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Nicolás Molano-González
Clinical Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
11 shared publications - Juan-Manuel Anaya
Universidad de la Costa, Barranquilla, Colombia
10 shared publications - Carolina Ramírez-Santana
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
7 shared publications - Diana M. Monsalve
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
7 shared publications - Yeny Acosta-Ampudia
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
7 shared publications - Adriana Rojas-Villarraga
Research Institute, Fundación Universitaria de Ciencias de la salud, Bogotá, Colombia
5 shared publications
Latest Publications
- Open Access
- 1 December 2019
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 2, 100016
Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
- 1 December 2019
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 2, 100016
Open AccessSubcutaneous abatacept in rheumatoid arthritis: A real-life experience
- 1 May 2019
- Published by Elsevier in Revue du Rhumatisme
- Vol. 86 (3) , 294-300
La résilience chez les patientes atteintes de maladies auto-immunes
- 1 May 2019
- Published by Elsevier in Revue du Rhumatisme
- Vol. 86 (3) , 294-300
La résilience chez les patientes atteintes de maladies auto-immunes
- Open Access
- 1 March 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 98, 24-32
Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity
- 1 March 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 98, 24-32
Open AccessCluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity
- 10 January 2019
- No. 4,p. 15-22
Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6.
Resilience, the ability to respond positively to adverse events, may be influenced by long-term stressors and autoimmune/inflammatory conditions such as systemic sclerosis (SSc). Since the immune system plays a role in the development of resilience, we aimed to evaluate the relationship between a panel of cytokines and resilience in patients with SSc. Thirty-five consecutive women with established SSc were involved in this exploratory study. Clinical characteristics, including severity of symptoms and resilience, a panel of 15 serum cytokines and 17 autoantibodies were assessed simultaneously. Multivariate methods were used to analyse the data. Interleukin-6 (IL-6) levels were associated with severity of symptoms (β=1.8395, p=0.04), and low resilience scores (β= -0.581120, p=0.02). Furthermore, resilience was not associated with clinical manifestations nor polyautoimmunity. Cytokine levels did not significantly differ between groups based on regular physical activity. The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
- 10 January 2019
- No. 4,p. 15-22
Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6.
Resilience, the ability to respond positively to adverse events, may be influenced by long-term stressors and autoimmune/inflammatory conditions such as systemic sclerosis (SSc). Since the immune system plays a role in the development of resilience, we aimed to evaluate the relationship between a panel of cytokines and resilience in patients with SSc. Thirty-five consecutive women with established SSc were involved in this exploratory study. Clinical characteristics, including severity of symptoms and resilience, a panel of 15 serum cytokines and 17 autoantibodies were assessed simultaneously. Multivariate methods were used to analyse the data. Interleukin-6 (IL-6) levels were associated with severity of symptoms (β=1.8395, p=0.04), and low resilience scores (β= -0.581120, p=0.02). Furthermore, resilience was not associated with clinical manifestations nor polyautoimmunity. Cytokine levels did not significantly differ between groups based on regular physical activity. The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
- 1 December 2018
- Published by Elsevier in Joint Bone Spine
- Vol. 85 (6) , 715-720
Resilience in women with autoimmune rheumatic diseases
- 1 December 2018
- Published by Elsevier in Joint Bone Spine
- Vol. 85 (6) , 715-720
Resilience in women with autoimmune rheumatic diseases
- 5 September 2018
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 56 (3) , 362-374
Sjögren’s Syndrome and Autoimmune Thyroid Disease: Two Sides of the Same Coin
- 5 September 2018
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 56 (3) , 362-374
Sjögren’s Syndrome and Autoimmune Thyroid Disease: Two Sides of the Same Coin
- Open Access
- 25 November 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 239
Cytokine and autoantibody clusters interaction in systemic lupus erythematosus
Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed. This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile, and a panel of 15 serum cytokines were measured simultaneously. Mixed-cluster methodology and bivariate analyses were used to define autoantibody and cytokine clusters and to identify associations between them and related variables. First, three clusters of autoantibodies were defined: (1) neutral, (2) antiphospholipid antibodies (APLA)-dominant, and (3) anti-dsDNA/ENA-dominant. Second, eight cytokines showed levels above the threshold thus making possible to find 4 clusters: (1) neutral, (2) chemotactic, (3) G-CSF dominant, and (4) IFNα/Pro-inflammatory. Furthermore, the disease activity was associated with cytokine clusters, which, in turn, were associated with autoantibody clusters. Finally, when all biomarkers were included, three clusters were found: (1) neutral, (2) chemotactic/APLA, and (3) IFN/dsDNA, which were also associated with disease activity. These results support the existence of three SLE cytokine-autoantibody driven subphenotypes. They encourage the practice of personalized medicine, and support proof-of-concept studies.
- 25 November 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 239
Open AccessCytokine and autoantibody clusters interaction in systemic lupus erythematosus
Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed. This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile, and a panel of 15 serum cytokines were measured simultaneously. Mixed-cluster methodology and bivariate analyses were used to define autoantibody and cytokine clusters and to identify associations between them and related variables. First, three clusters of autoantibodies were defined: (1) neutral, (2) antiphospholipid antibodies (APLA)-dominant, and (3) anti-dsDNA/ENA-dominant. Second, eight cytokines showed levels above the threshold thus making possible to find 4 clusters: (1) neutral, (2) chemotactic, (3) G-CSF dominant, and (4) IFNα/Pro-inflammatory. Furthermore, the disease activity was associated with cytokine clusters, which, in turn, were associated with autoantibody clusters. Finally, when all biomarkers were included, three clusters were found: (1) neutral, (2) chemotactic/APLA, and (3) IFN/dsDNA, which were also associated with disease activity. These results support the existence of three SLE cytokine-autoantibody driven subphenotypes. They encourage the practice of personalized medicine, and support proof-of-concept studies.
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 850
SAT0205 Long-term drug survival and causes of discontinuation of subcutaneous abatacept in rheumatoid arthritis: 32-month results from a prospective cohort study
Background Survival time or time to discontinuation of medication is a surrogate of the long-term impact on the course of disease in real life. It reflects clinical effectiveness in the absence of significant adverse events [1]. Treatment discontinuation can result from loss of efficacy or safety concerns, but prognostic factors for patient retention have not been explored thoroughly despite data for abatacept and other biologics being available from national registries [2]. Objectives To assess drug survival of subcutaneous (SC) abatacept among patients with rheumatoid arthritis (RA) according to treatment background. Methods This was a prospective study in which well-characterized patients with RA (by 1987 ACR criteria) were assessed from April 2014 to December 2016. Each patient was evaluated by a rheumatologist in a single rheumatology outpatient private center in Bogotá, Colombia. Patients were stratified by treatment background: (n=54) biologic-naïve, (n=24) switched from IV to SC abatacept administration, and (n=51) inadequate response to at least 1 biologic disease-modifying antirheumatic drug. The Mantel-Haenszel test was used to test if there were any differences in the survival curves among groups. The test was performed by the survdiff function of the “survival” R package [3]. Results A total of 129 patients were included. Baseline characteristics of patients were as follows: female gender 86%, mean age 52±13 years, median disease duration 10 (IQR 11) years, Rheumatoid Factor positive 94%, Anti-Cyclic Citrullinated Peptide Antibodies 89%, and erosive phenotype 35%. At baseline, mean DAS28 and RAPID3 were 5.4±1.3 and 16.6±6.8, respectively. SC abatacept monotherapy was reported in 27%. Demographics and disease characteristics were similar in all groups, except for baseline DAS28 and RAPID3 in switch group (pConclusions Our results disclose a similar drug survival of SC abatacept regardless of treatment background. Patients switching from IV to SC formulation of abatacept had lower activity and functional impairment at baseline, and survival tends to be higher through follow-up. The insurance-related limitations is a reality in Latin American countries, and could have a negatively impact on survival time of several drugs. References Nüßlein HG, et al. BMC Musculoskelet Disord. 2015;16:176. Souto A, et al. Rheumatology (Oxford). 2016;55(3):523–34. Therneau, T. and Grambsch, P.M. 2000. References Acknowledgements The authors are grateful to all the members of the Center of Dermatology and Rheumatology (FUNINDERMA) for their contribution to this work. Disclosure of Interest None declared
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 850
SAT0205 Long-term drug survival and causes of discontinuation of subcutaneous abatacept in rheumatoid arthritis: 32-month results from a prospective cohort study
Background Survival time or time to discontinuation of medication is a surrogate of the long-term impact on the course of disease in real life. It reflects clinical effectiveness in the absence of significant adverse events [1]. Treatment discontinuation can result from loss of efficacy or safety concerns, but prognostic factors for patient retention have not been explored thoroughly despite data for abatacept and other biologics being available from national registries [2]. Objectives To assess drug survival of subcutaneous (SC) abatacept among patients with rheumatoid arthritis (RA) according to treatment background. Methods This was a prospective study in which well-characterized patients with RA (by 1987 ACR criteria) were assessed from April 2014 to December 2016. Each patient was evaluated by a rheumatologist in a single rheumatology outpatient private center in Bogotá, Colombia. Patients were stratified by treatment background: (n=54) biologic-naïve, (n=24) switched from IV to SC abatacept administration, and (n=51) inadequate response to at least 1 biologic disease-modifying antirheumatic drug. The Mantel-Haenszel test was used to test if there were any differences in the survival curves among groups. The test was performed by the survdiff function of the “survival” R package [3]. Results A total of 129 patients were included. Baseline characteristics of patients were as follows: female gender 86%, mean age 52±13 years, median disease duration 10 (IQR 11) years, Rheumatoid Factor positive 94%, Anti-Cyclic Citrullinated Peptide Antibodies 89%, and erosive phenotype 35%. At baseline, mean DAS28 and RAPID3 were 5.4±1.3 and 16.6±6.8, respectively. SC abatacept monotherapy was reported in 27%. Demographics and disease characteristics were similar in all groups, except for baseline DAS28 and RAPID3 in switch group (pConclusions Our results disclose a similar drug survival of SC abatacept regardless of treatment background. Patients switching from IV to SC formulation of abatacept had lower activity and functional impairment at baseline, and survival tends to be higher through follow-up. The insurance-related limitations is a reality in Latin American countries, and could have a negatively impact on survival time of several drugs. References Nüßlein HG, et al. BMC Musculoskelet Disord. 2015;16:176. Souto A, et al. Rheumatology (Oxford). 2016;55(3):523–34. Therneau, T. and Grambsch, P.M. 2000. References Acknowledgements The authors are grateful to all the members of the Center of Dermatology and Rheumatology (FUNINDERMA) for their contribution to this work. Disclosure of Interest None declared
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 575
FRI0238 Effect of baseline anti-cyclic citrullinated peptide 3 antibody titre on long-term drug survival of subcutaneous abatacept in rheumatoid arthritis: a prospective cohort study
Background Clinical response to biologics varies widely between individuals with rheumatoid arthritis (RA). To date, there are few, and in some cases, conflicting results in the personalized approach of patients with RA treated with abatacept. Only the seropositive subphenotype (anti-cyclic citrullinated peptide, CCP) was validated in several populations, including a real-life registry (ORA) [1], and non-inferiority trial (AMPLE) [2]. Objectives To assess whether baseline anti-CCP3 antibody status and concentration correlated with drug survival of subcutaneous (SC) abatacept among patients with RA in a real-world setting. Methods This was a prospective study in which well-characterized patients with RA (by 1987 ACR criteria) were included from April 2014 to December 2016. Patients were evaluated at a single rheumatology outpatient center in Bogotá, Colombia. Baseline anti-CCP3 antibody status (positive/negative) and concentration were determined using an anti-CCP3 IgG ELISA (INOVA Diagnostics). Patients with a baseline anti-CCP3 IgG concentration of ≥20 U were considered to be positive and were further divided into equal quartiles according to concentration [Q1–Q4 (highest concentration)]. The Cox proportional hazards regression model was used to test if there were any differences in drug survival curves according to baseline anti-CCP3 antibody status and concentration. The test was performed by the coxph function of the “survival” R package [3]. Results A total of 129 patients were included. Baseline characteristics: female gender 86%, mean age 52±13 years, median disease duration 10 (IQR 11) years, and erosions 35%. Treatment background was as follows: biologic-naïve (n=54), switched from IV to SC abatacept administration (n=24), and inadequate response to at least 1 biologic disease-modifying antirheumatic drug (n=51). Forty-three patients (33%) discontinued treatment. The most frequent reasons for drug suspension were loss of efficacy. Rheumatoid Factor and anti-CCP3 was positive in 94%, and 89%, respectively. Median titre of anti-CCP3 was 248 U (IQR 352), and number of patients in each quartile group were Q1 (22–122)=21; Q2 (123–248)=20; Q3 (249–475)=19; Q4 (476–1544)=19. According to Cox proportional hazards regression model (Fig.1), there were significant differences between survival curves for Q1 (HR 0.1; 0.02–0.60 95% IC; p=0.011), Q2 (HR 0.2; 0.06–0.94 95% IC; p=0.041), and Q3 (HR 0.2; 0.04–0.85 95% IC; p=0.030), compared to negative group at month 32. Conclusions Baseline anti-CCP3 positivity was associated with a better response for SC abatacept in a real-world setting. Patients with lowest baseline anti-CCP3 antibody concentrations had better drug survival than patients with higher concentrations. Our results highlight the importance of identification of factors associated with response to biologics in order to optimize treatment and reduce costs. References Sokolove J, et al. Ann Rheum Dis. 2016;75(4):709–14. Gottenberg JE, et al. Ann Rheum Dis. 2012;71(11):1815–9. Therneau,T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Springer-Verlag, 2000. References Disclosure of Interest None declared
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 575
FRI0238 Effect of baseline anti-cyclic citrullinated peptide 3 antibody titre on long-term drug survival of subcutaneous abatacept in rheumatoid arthritis: a prospective cohort study
Background Clinical response to biologics varies widely between individuals with rheumatoid arthritis (RA). To date, there are few, and in some cases, conflicting results in the personalized approach of patients with RA treated with abatacept. Only the seropositive subphenotype (anti-cyclic citrullinated peptide, CCP) was validated in several populations, including a real-life registry (ORA) [1], and non-inferiority trial (AMPLE) [2]. Objectives To assess whether baseline anti-CCP3 antibody status and concentration correlated with drug survival of subcutaneous (SC) abatacept among patients with RA in a real-world setting. Methods This was a prospective study in which well-characterized patients with RA (by 1987 ACR criteria) were included from April 2014 to December 2016. Patients were evaluated at a single rheumatology outpatient center in Bogotá, Colombia. Baseline anti-CCP3 antibody status (positive/negative) and concentration were determined using an anti-CCP3 IgG ELISA (INOVA Diagnostics). Patients with a baseline anti-CCP3 IgG concentration of ≥20 U were considered to be positive and were further divided into equal quartiles according to concentration [Q1–Q4 (highest concentration)]. The Cox proportional hazards regression model was used to test if there were any differences in drug survival curves according to baseline anti-CCP3 antibody status and concentration. The test was performed by the coxph function of the “survival” R package [3]. Results A total of 129 patients were included. Baseline characteristics: female gender 86%, mean age 52±13 years, median disease duration 10 (IQR 11) years, and erosions 35%. Treatment background was as follows: biologic-naïve (n=54), switched from IV to SC abatacept administration (n=24), and inadequate response to at least 1 biologic disease-modifying antirheumatic drug (n=51). Forty-three patients (33%) discontinued treatment. The most frequent reasons for drug suspension were loss of efficacy. Rheumatoid Factor and anti-CCP3 was positive in 94%, and 89%, respectively. Median titre of anti-CCP3 was 248 U (IQR 352), and number of patients in each quartile group were Q1 (22–122)=21; Q2 (123–248)=20; Q3 (249–475)=19; Q4 (476–1544)=19. According to Cox proportional hazards regression model (Fig.1), there were significant differences between survival curves for Q1 (HR 0.1; 0.02–0.60 95% IC; p=0.011), Q2 (HR 0.2; 0.06–0.94 95% IC; p=0.041), and Q3 (HR 0.2; 0.04–0.85 95% IC; p=0.030), compared to negative group at month 32. Conclusions Baseline anti-CCP3 positivity was associated with a better response for SC abatacept in a real-world setting. Patients with lowest baseline anti-CCP3 antibody concentrations had better drug survival than patients with higher concentrations. Our results highlight the importance of identification of factors associated with response to biologics in order to optimize treatment and reduce costs. References Sokolove J, et al. Ann Rheum Dis. 2016;75(4):709–14. Gottenberg JE, et al. Ann Rheum Dis. 2012;71(11):1815–9. Therneau,T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Springer-Verlag, 2000. References Disclosure of Interest None declared
- Open Access
- 1 February 2017
- Published by Elsevier in Journal of Autoimmunity
- Vol. 77, 123-138
A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia
- 1 February 2017
- Published by Elsevier in Journal of Autoimmunity
- Vol. 77, 123-138
Open AccessA comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia